FDA Approval Insulin Life Science Pharma Companies 
XTalks
FEBRUARY 21, 2024
There are currently no FDA-approved drug therapies for MASH, and the disease is characterized by excess fat accumulation and inflammation in the liver, which leads to liver scarring or fibrosis. It has been approved for treating diabetes and obesity.
XTalks
AUGUST 17, 2020
In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. Cue Biopharma has an autoimmune disease collaboration with Merck, from which early data from a type 1 diabetes program was released earlier this year by the pharma company.
XTalks
FEBRUARY 14, 2024
US drug pricing has been under fire for many years and things took a significant turn last year when the three major insulin makers (Eli Lilly, Sanofi and Novo Nordisk) decided to slash the price of their insulin products and agreed to cap out-of-pocket costs at $35 per month for patients with insurance coverage.
Expert insights. Personalized for you.
59 
Let's personalize your content